NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

36.2M

Vuru Grade

30.66/100

Current Price

$0.70
-0.0157 (-2.19%)

Stability Price

$0.62
Overvalued by 10.80%

Company Metrics

  • 0 P/E
  • 34.45 P/S
  • 6.45 P/B
  • -0.317 EPS
  • -2,345.19% Cash ROIC
  • 3.60 Cash Ratio
  • 0.00 / N/A % Dividend
  • 172,126.00 Avg. Vol.
  • 38.18M Shares
  • 36.2M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common ...
GlobeNewswire (press release) - Mar 20, 2014
EMERYVILLE, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it has priced an ...
NovaBay Pharmaceuticals to Present Successful Patient Case Histories of i-Lid ...
Yahoo News - Oct 14, 2014
EMERYVILLE, CA / ACCESSWIRE /October 14, 2014 / NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that ...
NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a ...
GlobeNewswire (press release) - Nov 12, 2014
12, 2014 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today reported third quarter 2014 financial ...
NovaBay Pharmaceuticals Receives 2 nd Major NeutroPhase Order for 150000 ...
Business Wire (press release) - Oct 27, 2014
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its partner ...
NovaBay off big after trial fails (NBY)
Seeking Alpha (registration) - Aug 20, 2014
The global study enrolled patients with adenoviral conjunctivitis in the U.S., India, Sri Lanka and Brazil. The endpoints were: measured clearing of bulbar conjunctival injection (red eye); eradication of adenovirus from tear film; spread of infection ...
NovaBay Pharmaceuticals, Inc. (NBY): NVC-422 Gives NovaBay Huge Growth ...
Seeking Alpha - Dec 9, 2013
NovaBay (NBY) is a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products.
NovaBay Pharmaceuticals Deploys Direct Sales Force to Market i-Lid Cleanser ...
Yahoo Finance UK - Aug 25, 2014
NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that its i-Lid Cleanser sales force has been deployed in 10 ...
NovaBay Pharmaceuticals Announces Direct US Marketing-Sales Campaign for ...
Business Wire (press release) - Jul 16, 2014
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infectives, announced today it will initiate a major ...
NovaBay Pharmaceuticals Will Feature i-Lid Cleanser for the First Time at ...
Business Wire (press release) - Sep 16, 2014
EMERYVILLE, CA--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that the company will ...
NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion of ...
GlobeNewswire (press release) - Dec 2, 2013
EMERYVILLE, Calif., and SHANGHAI, China, Dec. 2, 2013 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing non-antibiotic antimicrobial products, today announced that it has ...